
(gan sye’ kloe vir)
Cytovene, Vitrasert, Zirgan
PREGNANCY CATEGORY C
Drug class
Antiviral
Therapeutic Actions
Antiviral activity; inhibits viral DNA replication in cytomegalovirus (CMV).
Indications
IV and implant: Treatment of CMV retinitis in immunocompromised patients, including patients with AIDS
IV: Prevention of CMV disease in transplant recipients at risk for CMV disease
Ophthalmic: Treatment of acute herpetic keratitis
Unlabeled use: Treatment of other CMV infections in immunocompromised patients
Contraindications and Cautions
Contraindicated with hypersensitivity to ganciclovir or acyclovir, lactation.
Use cautiously with cytopenia, history of cytopenic reactions, impaired renal function, pregnancy.
Available Forms
Powder for injection—500 mg/vial; ocular implant—4.5 mg; ophthalmic gel—0.15%
Dosages
Adults
CMV retinitis: Initial dose, 5 mg/kg given IV at a constant rate over 1 hr, every 12 hr for 14–21 days. For maintenance, 5 mg/kg given by IV infusion over 1 hr once daily, 7 days/wk or 6 mg/kg once daily, 5 days/wk. Implant surgically placed in affected eye every 5–8 mo.
Patients 2 yr and older
Ophthalmic gel: 1 drop in affected eye(s) five times daily (approximately every 3 hr while awake) until ulcer heals. Maintenance dose, 1 drop three times daily for 7 days.
Pediatric patients
Safety and efficacy not established. Use only if benefit outweighs potential carcinogenesis and reproductive toxicity.
Patients with renal impairment
|
|

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

